NZ516535A - Use of Interleukin-18 binding protein (IL-18BP) as an inhibitor for medicaments suitable to treat tumor metastasis - Google Patents

Use of Interleukin-18 binding protein (IL-18BP) as an inhibitor for medicaments suitable to treat tumor metastasis

Info

Publication number
NZ516535A
NZ516535A NZ516535A NZ51653500A NZ516535A NZ 516535 A NZ516535 A NZ 516535A NZ 516535 A NZ516535 A NZ 516535A NZ 51653500 A NZ51653500 A NZ 51653500A NZ 516535 A NZ516535 A NZ 516535A
Authority
NZ
New Zealand
Prior art keywords
cells
hse
inhibitor
action
production
Prior art date
Application number
NZ516535A
Other languages
English (en)
Inventor
Charles Dinarello
Original Assignee
Ares Trading S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading S filed Critical Ares Trading S
Publication of NZ516535A publication Critical patent/NZ516535A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ516535A 1999-07-22 2000-07-17 Use of Interleukin-18 binding protein (IL-18BP) as an inhibitor for medicaments suitable to treat tumor metastasis NZ516535A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13104799A IL131047A0 (en) 1999-07-22 1999-07-22 Use of il-18 inhibitors
PCT/IL2000/000419 WO2001007480A2 (en) 1999-07-22 2000-07-17 Use of interleukin-18 inhibitors to inhibit tumor metastasis

Publications (1)

Publication Number Publication Date
NZ516535A true NZ516535A (en) 2004-04-30

Family

ID=11073044

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ516535A NZ516535A (en) 1999-07-22 2000-07-17 Use of Interleukin-18 binding protein (IL-18BP) as an inhibitor for medicaments suitable to treat tumor metastasis

Country Status (31)

Country Link
US (1) US7741276B2 (US07585860-20090908-C00150.png)
EP (1) EP1206274B1 (US07585860-20090908-C00150.png)
JP (1) JP4827352B2 (US07585860-20090908-C00150.png)
KR (1) KR100682219B1 (US07585860-20090908-C00150.png)
CN (1) CN1173736C (US07585860-20090908-C00150.png)
AR (1) AR024907A1 (US07585860-20090908-C00150.png)
AT (1) ATE363288T1 (US07585860-20090908-C00150.png)
AU (1) AU782478B2 (US07585860-20090908-C00150.png)
BG (1) BG65800B1 (US07585860-20090908-C00150.png)
BR (1) BR0012675A (US07585860-20090908-C00150.png)
CA (1) CA2380216C (US07585860-20090908-C00150.png)
CY (1) CY1107932T1 (US07585860-20090908-C00150.png)
CZ (1) CZ302114B6 (US07585860-20090908-C00150.png)
DE (2) DE60035049T2 (US07585860-20090908-C00150.png)
DK (1) DK1206274T3 (US07585860-20090908-C00150.png)
EA (1) EA005419B1 (US07585860-20090908-C00150.png)
EE (1) EE04838B1 (US07585860-20090908-C00150.png)
ES (1) ES2186596T3 (US07585860-20090908-C00150.png)
HK (1) HK1048248B (US07585860-20090908-C00150.png)
HU (1) HU228780B1 (US07585860-20090908-C00150.png)
IL (2) IL131047A0 (US07585860-20090908-C00150.png)
MX (1) MXPA02000838A (US07585860-20090908-C00150.png)
NO (1) NO329827B1 (US07585860-20090908-C00150.png)
NZ (1) NZ516535A (US07585860-20090908-C00150.png)
PL (1) PL202477B1 (US07585860-20090908-C00150.png)
PT (1) PT1206274E (US07585860-20090908-C00150.png)
SK (1) SK287522B6 (US07585860-20090908-C00150.png)
TR (1) TR200200169T2 (US07585860-20090908-C00150.png)
UA (1) UA73745C2 (US07585860-20090908-C00150.png)
WO (1) WO2001007480A2 (US07585860-20090908-C00150.png)
ZA (1) ZA200200390B (US07585860-20090908-C00150.png)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110032012A (ko) 2000-02-10 2011-03-29 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
US6894155B2 (en) 2000-10-11 2005-05-17 Viron Therapeutics Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
WO2004032837A2 (en) * 2002-10-08 2004-04-22 Ares Trading S.A. The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
ATE517917T1 (de) 2005-06-03 2011-08-15 Ares Trading Sa Herstellung eines rekombinanten il-18-bindenden proteins
SI1891088T1 (sl) 2005-06-10 2012-02-29 Ares Trading Sa Postopek za äśiĺ äśenje il-18 vezavnega proteina
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
US9812033B2 (en) * 2013-03-06 2017-11-07 Venkatesh R. Chari Tactile graphic display
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332668T2 (de) * 1992-09-02 2003-12-18 Isis Pharmaceutical Inc Beeinflussing der zelladhäsie durch oligonukleotide
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
ID22975A (id) * 1997-03-18 1999-12-23 Basf Ag Metode dan komposisi untuk memodulasi respons terhadap kortikosteroid
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use

Also Published As

Publication number Publication date
NO20020153D0 (no) 2002-01-11
DE1206274T1 (de) 2002-11-14
IL147675A (en) 2009-05-04
KR100682219B1 (ko) 2007-02-12
EE200200032A (et) 2003-02-17
CZ2002195A3 (cs) 2002-06-12
CN1173736C (zh) 2004-11-03
DE60035049T2 (de) 2007-09-27
BR0012675A (pt) 2002-04-09
EA200200189A1 (ru) 2002-12-26
BG65800B1 (bg) 2009-12-31
NO20020153L (no) 2002-03-11
US7741276B2 (en) 2010-06-22
DE60035049D1 (de) 2007-07-12
UA73745C2 (en) 2005-09-15
CN1364086A (zh) 2002-08-14
EA005419B1 (ru) 2005-02-24
AU782478B2 (en) 2005-08-04
JP4827352B2 (ja) 2011-11-30
SK882002A3 (en) 2002-07-02
WO2001007480A2 (en) 2001-02-01
HK1048248A1 (en) 2003-03-28
HK1048248B (zh) 2005-04-22
MXPA02000838A (es) 2002-07-30
PL202477B1 (pl) 2009-06-30
AU5843200A (en) 2001-02-13
AR024907A1 (es) 2002-10-30
CA2380216C (en) 2012-01-31
CA2380216A1 (en) 2001-02-01
HUP0202107A3 (en) 2005-01-28
WO2001007480A3 (en) 2001-05-10
ZA200200390B (en) 2003-04-30
SK287522B6 (sk) 2011-01-04
CY1107932T1 (el) 2013-09-04
HUP0202107A2 (en) 2002-10-28
CZ302114B6 (cs) 2010-10-20
PL353732A1 (en) 2003-12-01
BRPI0012675B1 (pt) 2001-02-01
NO329827B1 (no) 2011-01-03
PT1206274E (pt) 2007-07-06
EP1206274A2 (en) 2002-05-22
BRPI0012675B8 (US07585860-20090908-C00150.png) 2021-05-25
HU228780B1 (en) 2013-05-28
EP1206274B1 (en) 2007-05-30
BG106311A (en) 2002-08-30
ES2186596T1 (es) 2003-05-16
KR20020027493A (ko) 2002-04-13
US20080003216A1 (en) 2008-01-03
TR200200169T2 (tr) 2002-06-21
IL131047A0 (en) 2001-01-28
EE04838B1 (et) 2007-06-15
ES2186596T3 (es) 2007-11-16
DK1206274T3 (da) 2007-08-13
JP2003505472A (ja) 2003-02-12
ATE363288T1 (de) 2007-06-15

Similar Documents

Publication Publication Date Title
US7741276B2 (en) Use of interleukin-18 inhibitors to inhibit tumor metastasis
Noack et al. Selected cytokine pathways in rheumatoid arthritis
Balkwill Tumour necrosis factor
Idriss et al. TNFα and the TNF receptor superfamily: Structure‐function relationship (s)
AU2001240636B2 (en) Use of il-18 inhibitors
Crowe et al. Specific induction of 80-kDa tumor necrosis factor receptor shedding in T lymphocytes involves the cytoplasmic domain and phosphorylation.
Winzen et al. Selective decrease in cell surface expression and mRNA level of the 55-kDa tumor necrosis factor receptor during differentiation of HL-60 cells into macrophage-like but not granulocyte-like cells.
Hosaka et al. The combined effects of anti-TNFα antibody and IL-1 receptor antagonist in human rheumatoid arthritis synovial membrane
CA2092914C (en) Synergism of tnf and il-4
Abe et al. The role of tumor necrosis factor receptors in cell signaling and the significance of soluble form levels in the serum
Totpal et al. Qualitative and quantitative differences in the cellular responses mediated through Fas antigen and tumor necrosis factor receptor
KR101769122B1 (ko) 케모카인 발현 조절제
US20020068060A1 (en) Cytokine antagonists
Roccaro et al. The Multiple Myeloma Bone Marrow Microenvironment

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: ARES TRADING S.A. (SWITZERLAND), CH

Free format text: OLD OWNER(S): YEDA RESEARCH AND DEVELOPMENT CO. LTD.

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 17 JUL 2020 BY CPA GLOBAL

Effective date: 20130607

EXPY Patent expired